Common cancer biomarkers

Christopher F. Basil, Yingdong Zhao, Katia Zavaglia, Ping Jin, Monica C. Panelli, Sonia Voiculescu, Susanna Mandruzzato, Hueling M. Lee, Barbara Seliger, Ralph S. Freedman, Phil R. Taylor, Nan Hu, Paola Zanovello, Francesco M. Marincola, Ena Wang

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

There is an increasing interest in complementing conventional histopathologic evaluation with molecular tools that could increase the sensitivity and specificity of cancer staging for diagnostic and prognostic purposes. This study strove to identify cancer-specific markers for the molecular detection of a broad range of cancer types. We used 373 archival samples inclusive of normal tissues of various lineages and benign or malignant tumors (predominantly colon, melanoma, ovarian, and esophageal cancers). All samples were processed identically and cohybridized with an identical reference RNA source to a custom-made cDNA array platform. The database was split into training (n = 201) and comparable prediction (n = 172) sets. Leave-one-out cross-validation and gene pairing analysis identified putative cancer biomarkers overexpressed by malignant lesions independent of tissue of derivation. In particular, seven gene pairs were identified with high predictive power (87%) in segregating malignant from benign lesions. Receiver operator characteristic curves based on the same genes could segregate malignant from benign tissues with 94% accuracy. The relevance of this study rests on the identification of a restricted number of biomarkers ubiquitously expressed by cancers of distinct histology. This has not been done before. These biomarkers could be used broadly to increase the sensitivity and accuracy of cancer staging and early detection of locoregional or systemic recurrence. Their selective expression by cancerous compared with paired normal tissues suggests an association with the oncogenic process resulting in stable expression during disease progression when the presently used differentiation markers are unreliable.

Original languageEnglish
Pages (from-to)2953-2961
Number of pages9
JournalCancer Research
Volume66
Issue number6
DOIs
Publication statusPublished - 15 Mar 2006
Externally publishedYes

Fingerprint

Tumor Biomarkers
Neoplasm Staging
Neoplasms
Biomarkers
Genes
Differentiation Antigens
Esophageal Neoplasms
Oligonucleotide Array Sequence Analysis
Ovarian Neoplasms
Colonic Neoplasms
Disease Progression
Melanoma
Histology
Databases
RNA
Recurrence
Sensitivity and Specificity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Basil, C. F., Zhao, Y., Zavaglia, K., Jin, P., Panelli, M. C., Voiculescu, S., ... Wang, E. (2006). Common cancer biomarkers. Cancer Research, 66(6), 2953-2961. https://doi.org/10.1158/0008-5472.CAN-05-3433

Common cancer biomarkers. / Basil, Christopher F.; Zhao, Yingdong; Zavaglia, Katia; Jin, Ping; Panelli, Monica C.; Voiculescu, Sonia; Mandruzzato, Susanna; Lee, Hueling M.; Seliger, Barbara; Freedman, Ralph S.; Taylor, Phil R.; Hu, Nan; Zanovello, Paola; Marincola, Francesco M.; Wang, Ena.

In: Cancer Research, Vol. 66, No. 6, 15.03.2006, p. 2953-2961.

Research output: Contribution to journalArticle

Basil, CF, Zhao, Y, Zavaglia, K, Jin, P, Panelli, MC, Voiculescu, S, Mandruzzato, S, Lee, HM, Seliger, B, Freedman, RS, Taylor, PR, Hu, N, Zanovello, P, Marincola, FM & Wang, E 2006, 'Common cancer biomarkers', Cancer Research, vol. 66, no. 6, pp. 2953-2961. https://doi.org/10.1158/0008-5472.CAN-05-3433
Basil CF, Zhao Y, Zavaglia K, Jin P, Panelli MC, Voiculescu S et al. Common cancer biomarkers. Cancer Research. 2006 Mar 15;66(6):2953-2961. https://doi.org/10.1158/0008-5472.CAN-05-3433
Basil, Christopher F. ; Zhao, Yingdong ; Zavaglia, Katia ; Jin, Ping ; Panelli, Monica C. ; Voiculescu, Sonia ; Mandruzzato, Susanna ; Lee, Hueling M. ; Seliger, Barbara ; Freedman, Ralph S. ; Taylor, Phil R. ; Hu, Nan ; Zanovello, Paola ; Marincola, Francesco M. ; Wang, Ena. / Common cancer biomarkers. In: Cancer Research. 2006 ; Vol. 66, No. 6. pp. 2953-2961.
@article{bee8bb80389f4710ad40f5ad0b30f4d3,
title = "Common cancer biomarkers",
abstract = "There is an increasing interest in complementing conventional histopathologic evaluation with molecular tools that could increase the sensitivity and specificity of cancer staging for diagnostic and prognostic purposes. This study strove to identify cancer-specific markers for the molecular detection of a broad range of cancer types. We used 373 archival samples inclusive of normal tissues of various lineages and benign or malignant tumors (predominantly colon, melanoma, ovarian, and esophageal cancers). All samples were processed identically and cohybridized with an identical reference RNA source to a custom-made cDNA array platform. The database was split into training (n = 201) and comparable prediction (n = 172) sets. Leave-one-out cross-validation and gene pairing analysis identified putative cancer biomarkers overexpressed by malignant lesions independent of tissue of derivation. In particular, seven gene pairs were identified with high predictive power (87{\%}) in segregating malignant from benign lesions. Receiver operator characteristic curves based on the same genes could segregate malignant from benign tissues with 94{\%} accuracy. The relevance of this study rests on the identification of a restricted number of biomarkers ubiquitously expressed by cancers of distinct histology. This has not been done before. These biomarkers could be used broadly to increase the sensitivity and accuracy of cancer staging and early detection of locoregional or systemic recurrence. Their selective expression by cancerous compared with paired normal tissues suggests an association with the oncogenic process resulting in stable expression during disease progression when the presently used differentiation markers are unreliable.",
author = "Basil, {Christopher F.} and Yingdong Zhao and Katia Zavaglia and Ping Jin and Panelli, {Monica C.} and Sonia Voiculescu and Susanna Mandruzzato and Lee, {Hueling M.} and Barbara Seliger and Freedman, {Ralph S.} and Taylor, {Phil R.} and Nan Hu and Paola Zanovello and Marincola, {Francesco M.} and Ena Wang",
year = "2006",
month = "3",
day = "15",
doi = "10.1158/0008-5472.CAN-05-3433",
language = "English",
volume = "66",
pages = "2953--2961",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Common cancer biomarkers

AU - Basil, Christopher F.

AU - Zhao, Yingdong

AU - Zavaglia, Katia

AU - Jin, Ping

AU - Panelli, Monica C.

AU - Voiculescu, Sonia

AU - Mandruzzato, Susanna

AU - Lee, Hueling M.

AU - Seliger, Barbara

AU - Freedman, Ralph S.

AU - Taylor, Phil R.

AU - Hu, Nan

AU - Zanovello, Paola

AU - Marincola, Francesco M.

AU - Wang, Ena

PY - 2006/3/15

Y1 - 2006/3/15

N2 - There is an increasing interest in complementing conventional histopathologic evaluation with molecular tools that could increase the sensitivity and specificity of cancer staging for diagnostic and prognostic purposes. This study strove to identify cancer-specific markers for the molecular detection of a broad range of cancer types. We used 373 archival samples inclusive of normal tissues of various lineages and benign or malignant tumors (predominantly colon, melanoma, ovarian, and esophageal cancers). All samples were processed identically and cohybridized with an identical reference RNA source to a custom-made cDNA array platform. The database was split into training (n = 201) and comparable prediction (n = 172) sets. Leave-one-out cross-validation and gene pairing analysis identified putative cancer biomarkers overexpressed by malignant lesions independent of tissue of derivation. In particular, seven gene pairs were identified with high predictive power (87%) in segregating malignant from benign lesions. Receiver operator characteristic curves based on the same genes could segregate malignant from benign tissues with 94% accuracy. The relevance of this study rests on the identification of a restricted number of biomarkers ubiquitously expressed by cancers of distinct histology. This has not been done before. These biomarkers could be used broadly to increase the sensitivity and accuracy of cancer staging and early detection of locoregional or systemic recurrence. Their selective expression by cancerous compared with paired normal tissues suggests an association with the oncogenic process resulting in stable expression during disease progression when the presently used differentiation markers are unreliable.

AB - There is an increasing interest in complementing conventional histopathologic evaluation with molecular tools that could increase the sensitivity and specificity of cancer staging for diagnostic and prognostic purposes. This study strove to identify cancer-specific markers for the molecular detection of a broad range of cancer types. We used 373 archival samples inclusive of normal tissues of various lineages and benign or malignant tumors (predominantly colon, melanoma, ovarian, and esophageal cancers). All samples were processed identically and cohybridized with an identical reference RNA source to a custom-made cDNA array platform. The database was split into training (n = 201) and comparable prediction (n = 172) sets. Leave-one-out cross-validation and gene pairing analysis identified putative cancer biomarkers overexpressed by malignant lesions independent of tissue of derivation. In particular, seven gene pairs were identified with high predictive power (87%) in segregating malignant from benign lesions. Receiver operator characteristic curves based on the same genes could segregate malignant from benign tissues with 94% accuracy. The relevance of this study rests on the identification of a restricted number of biomarkers ubiquitously expressed by cancers of distinct histology. This has not been done before. These biomarkers could be used broadly to increase the sensitivity and accuracy of cancer staging and early detection of locoregional or systemic recurrence. Their selective expression by cancerous compared with paired normal tissues suggests an association with the oncogenic process resulting in stable expression during disease progression when the presently used differentiation markers are unreliable.

UR - http://www.scopus.com/inward/record.url?scp=33645528385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645528385&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-3433

DO - 10.1158/0008-5472.CAN-05-3433

M3 - Article

VL - 66

SP - 2953

EP - 2961

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 6

ER -